FDA approves Syndax’s Revuforj to treat leukaemia
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...
REVUFORJ: Early FDA Approval Boosts Market Confidence and Buy Rating
BTIG analyst Justin Zelin has reiterated their bullish stance on SNDX stock, giving a Buy rating on November 15.Don't Miss our Black Friday ...
The Pharma Letter3m
Syndax earns its 2nd drug approval in 2024 with Revuforj
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals’ Revuforj (revumenib). Revuforj is the first ...
Syndax Pharmaceuticals Gains ‘Buy’ Rating Amidst Revuforj’s FDA Approval and Promising Market Prospects
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...
STAT15h
Syndax wins U.S. approval for leukemia treatment
The pill, called Revuforj, is the first medicine in a class of drugs called menin inhibitors to reach the market. Revuforj ...
pharmaphorum6h
Syndax gets FDA okay for first-in-class leukaemia drug
Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...
Medscape2h
Revumenib Approved for R/R Acute Leukemia With KMT2A Translocation
The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...
Cure Today2d
FDA Approves Revuforj for Relapsed/Refractory Acute Leukemia Subset
Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.
US FDA approves Syndax's blood cancer drug
The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...
oncnursingnews2d
FDA Approves Revumenib for Relapsed, Refractory Acute Leukemia With a KMT2A Translocation
The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with ...
MedPage Today2d
FDA Approves First Menin Inhibitor for Acute Leukemia
The FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older with relapsed/refractory acute leukemia and a lysine methyltransferase 2A gene ( ...